

J. Woinach

Page 1 of 7  
#10  
40  
3-20-07

1632

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/462,993

DATE: 09/15/2000  
TIME: 14:29:33

Input Set : A:\017753-122.APP  
Output Set: N:\CRF3\09152000\I462993.raw

3 <110> APPLICANT: KIENY, Marie-Paule  
4 BALLOUL, Jean-Marc  
5 BIZOUARNE, Nadine  
7 <120> TITLE OF INVENTION: ANTITUMORAL COMPOSITION BASED ON IMMUNOGENIC  
8 POLYPEPTIDE WITH MODIFIED CELL LOCATION  
10 <130> FILE REFERENCE: 017753-122  
12 <140> CURRENT APPLICATION NUMBER: 09/462,993  
13 <141> CURRENT FILING DATE: 2000-04-17  
15 <150> PRIOR APPLICATION NUMBER: PCT/FR98/01576  
16 <151> PRIOR FILING DATE: 1998-07-17  
18 <150> PRIOR APPLICATION NUMBER: FR 97/09152  
19 <151> PRIOR FILING DATE: 1997-07-18  
21 <160> NUMBER OF SEQ ID NOS: 23  
23 <170> SOFTWARE: PatentIn Ver. 2.2  
25 <210> SEQ ID NO: 1  
26 <211> LENGTH: 243  
27 <212> TYPE: PRT  
28 <213> ORGANISM: Artificial Sequence  
30 <220> FEATURE:  
31 <223> OTHER INFORMATION: Description of Artificial Sequence: Derived from  
32 human papillomavirus, strain HPV-16, E6 protein  
33 fused F protein signals, clone E6\*TMF.  
35 <400> SEQUENCE: 1  
36 Met Gly Leu Lys Val Asn Val Ser Ala Ile Phe Met Ala Val Leu Leu  
37 1 5 10 15  
39 Thr Leu Gln Thr Pro Thr Gly Gln Ile His Trp Gly Met His Gln Lys  
40 20 25 30  
42 Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro Arg Lys Leu Pro  
43 35 40 45  
45 Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp Ile Ile Leu Glu  
46 50 55 60  
48 Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp Phe  
49 65 70 75 80  
51 Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly Asn Pro Tyr Ala  
52 85 90 95  
54 Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys Ile Ser Glu Tyr Arg  
55 100 105 110  
57 His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Tyr Asn  
58 115 120 125  
60 Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn Cys Gln Lys Pro  
61 130 135 140  
63 Leu Gln Arg His Leu Asp Lys Lys Gln Arg Phe His Asn Ile Arg Gly  
64 145 150 155 160  
66 Arg Trp Thr Gly Arg Cys Met Ser Cys Arg Ser Ser Arg Thr Arg  
67 165 170 175  
69 Arg Glu Thr Gln Leu Gly Leu Ser Ser Thr Ser Ile Val Tyr Ile Leu  
70 180 185 190

ENTERED

RECEIVED

SEP 25 2000

TECH CENTER 1000/2000

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/462,993

DATE: 09/15/2000  
TIME: 14:29:33

Input Set : A:\017753-122.APP  
Output Set: N:\CRF3\09152000\I462993.raw

```

72 Ile Ala Val Cys Leu Gly Gly Leu Ile Gly Ile Pro Ala Leu Ile Cys
73      195      200      205
75 Cys Cys Arg Gly Arg Cys Asn Lys Lys Gly Glu Gln Val Gly Met Ser
76      210      215      220
78 Arg Pro Gly Leu Lys Pro Asp Leu Thr Gly Thr Ser Lys Ser Tyr Val
79 225      230      235      240
81 Arg Ser Leu
84 <210> SEQ ID NO: 2
85 <211> LENGTH: 185
86 <212> TYPE: PRT
87 <213> ORGANISM: Artificial Sequence
89 <220> FEATURE:
90 <223> OTHER INFORMATION: Derived from human papillomavirus, strain
91   HPV-16, E7 fusion signals of the rabies
92   glycoprotein, clone E7*TMR.
94 <400> SEQUENCE: 2
95 Met Val Pro Gln Ala Leu Leu Phe Val Pro Leu Leu Val Phe Pro Leu
96      1      5      10      15
98 Cys Phe Gly Lys Phe Pro Ile Gly Ser Met His Gly Asp Thr Pro Thr
99      20      25      30
101 Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr Gln Leu Asn
102      35      40      45
104 Asp Ser Ser Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala
105      50      55      60
107 Glu Pro Asp Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys
108      65      70      75      80
110 Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg
111      85      90      95
113 Thr Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile
114      100      105      110
116 Cys Ser Gln Lys Pro Arg Ser Tyr Val Leu Leu Ser Ala Gly Ala Leu
117      115      120      125
119 Thr Ala Leu Met Leu Ile Ile Phe Leu Met Thr Cys Cys Arg Arg Val
120      130      135      140
122 Asn Arg Ser Glu Pro Thr Gln His Asn Leu Arg Gly Thr Gly Arg Glu
123 145      150      155      160
125 Val Ser Val Thr Pro Gln Ser Gly Lys Ile Ile Ser Ser Trp Glu Ser
126      165      170      175
128 His Lys Ser Gly Gly Glu Thr Arg Leu
129      180      185
133 <210> SEQ ID NO: 3
134 <211> LENGTH: 36
135 <212> TYPE: DNA
136 <213> ORGANISM: Artificial Sequence
138 <220> FEATURE:
139 <223> OTHER INFORMATION: Derived from human papillomavirus, strain
140   HPV-16, synthetic oligonucleotide oTG5118 (E7
141   deleted 21 26), anti-sense.
143 <400> SEQUENCE: 3

```

RECEIVED

SEP 25 2000

TECH CENTER 1600/2900

RAW SEQUENCE LISTING                      DATE: 09/15/2000  
 PATENT APPLICATION: US/09/462,993        TIME: 14:29:33

Input Set : A:\017753-122.APP  
 Output Set: N:\CRF3\09152000\I462993.raw

```

144 tctgagctgt catttaattg agttgtctct ggttgc           36
147 <210> SEQ ID NO: 4
148 <211> LENGTH: 42
149 <212> TYPE: DNA
150 <213> ORGANISM: Artificial Sequence
152 <220> FEATURE:
153 <223> OTHER INFORMATION: Derivated from rabies virus, mutagenesis
154     oligonucleotide oTG5745, non anti-sense
156 <400> SEQUENCE: 4
157 tgcactcagt aatacatagg atccaatagg gaatttccca aa           42
160 <210> SEQ ID NO: 5
161 <211> LENGTH: 38
162 <212> TYPE: DNA
163 <213> ORGANISM: Artificial Sequence
165 <220> FEATURE:
166 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG6390, anti-sense.
168 <400> SEQUENCE: 5
169 gtatctccat gcatggatcc tgcagggttt ctctacgt           38
172 <210> SEQ ID NO: 6
173 <211> LENGTH: 36
174 <212> TYPE: DNA
175 <213> ORGANISM: Artificial Sequence
177 <220> FEATURE:
178 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG6880, anti-sense.
180 <400> SEQUENCE: 6
181 ggatccgccca tggtagatct tggtttctga gaacag           36
184 <210> SEQ ID NO: 7
185 <211> LENGTH: 32
186 <212> TYPE: DNA
187 <213> ORGANISM: Artificial Sequence
189 <220> FEATURE:
190 <223> OTHER INFORMATION: Derivative from rabies virus, strain
191     HPV-16, synthetic oligonucleotide oTG5377 (E6
192     deleted 111 to 115), anti-sense.
194 <400> SEQUENCE: 7
195 tgtccagatg tctttgcagt ggcctttgac ag           32
198 <210> SEQ ID NO: 8
199 <211> LENGTH: 34
200 <212> TYPE: DNA
201 <213> ORGANISM: Artificial Sequence
203 <220> FEATURE:
204 <223> OTHER INFORMATION: Synthetic oligonucleotide oT10829, non anti-sense.
206 <400> SEQUENCE: 8
207 gcgcgctcta gaattatggg tctcaagggtg aacg           34
210 <210> SEQ ID NO: 9
211 <211> LENGTH: 35
212 <212> TYPE: DNA
213 <213> ORGANISM: Artificial Sequence
215 <220> FEATURE:

```

RECEIVED

SEP 25 2003

TECH CENTER 1600/2900

RAW SEQUENCE LISTING                      DATE: 09/15/2000  
PATENT APPLICATION: US/09/462,993        TIME: 14:29:33

Input Set : A:\017753-122.APP  
Output Set: N:\CRF3\09152000\I462993.raw

216 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG10830, anti-sense.  
218 <400> SEQUENCE: 9  
219 cagttctctt ttggtgcatg ccccaatgga ttgga                      35  
222 <210> SEQ ID NO: 10  
223 <211> LENGTH: 38  
224 <212> TYPE: DNA  
225 <213> ORGANISM: Artificial Sequence  
227 <220> FEATURE:  
228 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG10835, non  
229 anti-sense.  
231 <400> SEQUENCE: 10  
232 atgctagtgc tcgataaacc cagctgggtt tctctacg                      38  
235 <210> SEQ ID NO: 11  
236 <211> LENGTH: 35  
237 <212> TYPE: DNA  
238 <213> ORGANISM: Artificial Sequence  
240 <220> FEATURE:  
241 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG10836, anti-sense.  
243 <400> SEQUENCE: 11  
244 tcaaatccat tggggcatgc accaaaagag aactg                      35  
247 <210> SEQ ID NO: 12  
248 <211> LENGTH: 38  
249 <212> TYPE: DNA  
250 <213> ORGANISM: Artificial Sequence  
252 <220> FEATURE:  
253 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG10833, non  
254 anti-sense.  
256 <400> SEQUENCE: 12  
257 cgtagagaaa cccagctggg ttatcgagc actagcat                      38  
260 <210> SEQ ID NO: 13  
261 <211> LENGTH: 36  
262 <212> TYPE: DNA  
263 <213> ORGANISM: Artificial Sequence  
265 <220> FEATURE:  
266 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG10834, anti-sense.  
268 <400> SEQUENCE: 13  
269 gcgggcatgc ggtacctcag agcgacctta catagg                      36  
272 <210> SEQ ID NO: 14  
273 <211> LENGTH: 32  
274 <212> TYPE: DNA  
275 <213> ORGANISM: Artificial Sequence  
277 <220> FEATURE:  
278 <223> OTHER INFORMATION: Derived from vaccinia virus, strain modified  
279 Ankara, synthetic oligonucleotide oTG7637 (PCR III  
280 region), non anti-sense.  
282 <400> SEQUENCE: 14  
283 gggggggaat tcagtaaact tgactaaatc tt                      32  
286 <210> SEQ ID NO: 15  
287 <211> LENGTH: 39

RECEIVED  
SEP 25 2000  
TECH CENTER 1600/2000

RAW SEQUENCE LISTING                      DATE: 09/15/2000  
 PATENT APPLICATION: US/09/462,993              TIME: 14:29:33

Input Set : A:\017753-122.APP  
 Output Set: N:\CRF3\09152000\I462993.raw

```

288 <212> TYPE: DNA
289 <213> ORGANISM: Artificial Sequence
291 <220> FEATURE:
292 <223> OTHER INFORMATION: Derivated from vaccinia virus, strain modified
293     Ankara, synthetic oligonucleotide oTG7638 (PCR III
294     region), anti-sense.
296 <400> SEQUENCE: 15
297 ggggggggat ccgagctcac cagccaccga aagagcaat           39
300 <210> SEQ ID NO: 16
301 <211> LENGTH: 32
302 <212> TYPE: DNA
303 <213> ORGANISM: Artificial Sequence
305 <220> FEATURE:
306 <223> OTHER INFORMATION: Derivated from vaccinia virus, strain modified
307     Ankara, synthetic oligonucleotide oTG7635 (PCR III
308     region), non anti-sense.
310 <400> SEQUENCE: 16
311 ggggggggat ccgaaaagtt ttataggtag tt           32
314 <210> SEQ ID NO: 17
315 <211> LENGTH: 30
316 <212> TYPE: DNA
317 <213> ORGANISM: Artificial Sequence
319 <220> FEATURE:
320 <223> OTHER INFORMATION: Derivated from vaccinia virus, strain modified
321     Ankara, synthetic oligonucleotide oTG7636 (PCR III
322     region), anti-sense.
324 <400> SEQUENCE: 17
325 gggggggaat tctttgtatt tacgtgaacg           30
328 <210> SEQ ID NO: 18
329 <211> LENGTH: 77
330 <212> TYPE: DNA
331 <213> ORGANISM: Artificial Sequence
333 <220> FEATURE:
334 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG10502, non
335     anti-sense.
337 <400> SEQUENCE: 18
338 agctttttat tctatactta aaaaatgaaa ataaactcga gttgtcaaag catcatctca 60
339 acactgactt gaggtac           77
342 <210> SEQ ID NO: 19
343 <211> LENGTH: 69
344 <212> TYPE: DNA
345 <213> ORGANISM: Artificial Sequence
347 <220> FEATURE:
348 <223> OTHER INFORMATION: Synthetic oligonucleotide oTG10503, anti-sense.
350 <400> SEQUENCE: 19
351 ctcaagtcag tggtagatg atgctttgac aactcgagtt tattttcatt tttaagtat 60
352 agaataaaa           69
355 <210> SEQ ID NO: 20
356 <211> LENGTH: 39

```

RECEIVED

SEP 25 2000

TECH CENTER 1600/2900

VERIFICATION SUMMARY                      DATE: 09/15/2000  
PATENT APPLICATION:    US/09/462,993        TIME: 14:29:34  
  
Input Set :    A:\017753-122.APP  
Output Set:    N:\CRF3\09152000\I462993.raw